As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D

Strategic R&D cuts have been a high priority for many pharma companies lately, from Moderna slashing R&D by 20% and discontinuing five clinical programs to Incyte eliminating several pipeline programs after a “strategic review.”